a 1120

A 1120 is a nonretinoid retinol-binding protein 4 (RBP4) antagonist (Ki: 8.3 nM), which disrupts the interaction between RBP4 and its binding partner transthyretin.

Anti-RatIgG1Antibody (RG11/39.4) is a mouse-derived IgG2c, κ antibody that acts as an inhibitor against rat IgG1.

Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor targeting VEGFR1/2/3, FGFR1/2/3, and PDGFRα/β.

BIBF 1202 is a VEGFR2 kinase inhibitor (IC50: 62 nM).

Regadenoson (CVT-3146) is an adenosine derivative and selective A2A adenosine receptor agonist with coronary vasodilating activity. Upon administration, regadenoson selectively binds to and activates the A2A adenosine receptor, which induces coronary vasodilation. This leads to an increase in coronary blood flow and enhances myocardial perfusion. Compared to adenosine, regadenoson has a longer half-life and shows higher selectivity towards the A2A adenosine receptor. This agent is a very weak agonist for the A1 adenosine receptor and has negligible affinity for the A2B and A3 adenosine receptors.

Nintedanib-13C,d3 is a 13C- and deuterium-labeled version of Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor that effectively blocks VEGFR1/2/3, FGFR1/2/3, and PDGFRα/β with IC50 values of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM, and 59 nM/65 nM, respectively.